Nicholas DeVito: Furthering our work in metastasis and immune evasion using a colon cancer mouse model
Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn about a paper he co-authored with colleagues published in Cancer Research:
“I have resubmitted my NIH/NCI K08 grant today.
This funding would be used to further our work in metastasis and immune evasion using a colon cancer mouse model that spreads to the liver like we see in human colorectal cancer. We study this model in parallel with matched primary/metastasis patient specimens.
Some of the preliminary data is described in our recent Cancer Research manuscript, where we have described the transcription factor Gli2 in tumors to promote Wnt and Prostaglandin signalling, and thus immunotherapy resistance which can be reversed with pharmacologic inhibitors.
The goal is to develop patient-specific immunotherapies in advanced colorectal cancer that work longer than chemotherapy with fewer long-term side effects. The need for better treatments at this time cannot be overstated, particularly given the rise in younger onset gastrointestinal cancers.”
Authors: Nicholas DeVito, Y-Van Nguyen, Michael Sturdivant, Michael Plebanek, Kaylee Villarreal, Nagendra Yarla, Vaibhav Jain, Michael Aksu, Georgia Beasley, Balamayooran Theivanthiran, Brent Hanks.
More posts featuring Nicholas DeVito.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023